facebook
twitter
rss
account
search
search
 

FDA approves new fibrillation drug

July 2, 2009 at 11:10 AM   |   Comments

WASHINGTON, July 2 (UPI) -- The U.S. Food and Drug Administration announced approval Thursday of Multaq tablets to help maintain normal heart rhythms in patients with heart disorders.

The FDA said Multaq (dronedarone) is designed to treat atrial fibrillation or atrial flutter in patients whose hearts have returned to normal rhythm or who will undergo drug or electric-shock treatment to restore a normal heart beat.

Since Multaq might cause critical adverse reactions, including death, in patients with recent severe heart failure, officials said Multag's drug's label will contain a boxed warning, the FDA's strongest warning, cautioning the drug should not be used by such people.

Multaq is manufactured by the French pharmaceutical company Sanofi-Aventis.

© 2009 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.
Most Popular
1
Psychedelic mushrooms enable a hyperconnected brain Psychedelic mushrooms enable a hyperconnected brain
2
Google working on pill to detect cancer Google working on pill to detect cancer
3
Sweet! App candy map a Halloween score Sweet! App candy map a Halloween score
4
SpaceX may soon start landing rockets on a platform after they've left Earth SpaceX may soon start landing rockets on a platform after they've left Earth
5
Why NASA is watching Ebola Why NASA is watching Ebola
Trending News
Around the Web
x
Feedback